Dr. Amir R. Haghighat, MD

Dr. Haghighat practices at Cardiovascular Surgical Institute of Northwest Florida in Panama City, Florida.

Dr. Haghighat's NPI, 1235197518, was assigned on May 3, 2006. Dr. Haghighat graduated from Perelman School of Med at the University of Pennsylvania in 1998. Dr. Haghighat holds Florida license ME96131.

Dr. Haghighat's primary practice is Cardiovascular Surgical Institute of Northwest Florida, at 625 W Baldwin Road Suite D, Panama City, FL 32405. The practice phone is (850) 820-7900.

Dr. Haghighat's primary practice is Cardiovascular Surgical Institute of Northwest Florida in Panama City, Florida. Dr. Haghighat is also affiliated with HCA Florida Gulf Coast Hospital. The medical group on file is Cardiovascular Institute of Northwest Florida. Dmand AI also links Dr. Haghighat to 3 more hospitals and 1 group practice or clinic, each named with a free account. Dr. Haghighat's employer is on file too: a surgery center (asc).

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Haghighat practices, 6 sites in all. Vendor and product names are available with a free account.

Interventional cardiology is Dr. Haghighat's primary specialty in the NPI Registry, under taxonomy code 207RI0011X. Dmand AI has Dr. Haghighat's licenses on file in 2 states: Florida and Louisiana.

CMS data shows 6,358 Medicare services from Dr. Haghighat across 47 procedure codes in 2024, for 2,232 Medicare patients. Medicare paid $645,684 for them.

CMS counts 2,232 Medicare patients who saw Dr. Haghighat in 2024. The largest group is 75 to 84, with 925 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 8% are also on Medicaid. Their average risk score is 1.45, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Haghighat's median patient age at 74, with 48% women.

In 2024, Dr. Haghighat wrote 6,182 Medicare Part D claims for 1,046 patients. 82% of them were for generic drugs. CMS names the drug for 5,935 of them, across 45 drugs with 11 or more claims each, at $1,214,019 in total drug cost. In 2023, CMS named 4,705 claims across 40 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Haghighat for performance year 2024, reported as part of a group. Dr. Haghighat accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 67 procedures of coronary angioplasty and stenting by Dr. Haghighat, more than 91% of the clinicians it reports for that procedure.

Leg revascularization (restoring blood flow): 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 5 papers to Dr. Haghighat, published from 2017 to 2025. Dr. Haghighat's most frequent co-authors are Wayne B. Batchelor, MD, Osvaldo Steven Gigliotti, MD and Gregory R. Giugliano, MD.

Dmand AI links Dr. Haghighat to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Carotid Stenosis, Heart Failure and Carotid Artery Diseases.

CMS Open Payments shows 852 general payments to Dr. Haghighat from 54 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 54% of the total. Gilead Sciences, Inc. paid the most, $25,797.

Dr. Haghighat graduated from Perelman School of Med at the University of Pennsylvania in 1998.